Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Qiagen NV - Hilden, Germany-based molecular diagnostics company - Records net sales of $500 million in the third quarter of 2022, down 7% year-on-year, as Covid-19 product group sales fell 43% at constant exchange rates to $83 million amid reduced demand. Adjusted diluted earnings per share fall to $0.53 compared to $0.58 in the same period in 2021. Raises its full-year 2022 outlook based on the strong results in the first nine months to date. Expects net sales to be about $2.25 billion at constant exchange rates, up from the prior outlook for at least $2.2 billion. Expects adjusted diluted earnings per share to be about $2.40 at constant exchange rates, up from for at least $2.30.
Current stock price: €42.02
12-month change: down 11%
Copyright 2022 Alliance News Limited. All Rights Reserved.